Access to unproven interventions outside of research during a pandemic is ethically
controversial because of its potential to increase harm to patients and undermine the
expedient initiation of clinical trials to produce reliable evidence on the safety and
effectiveness of therapeutic candidates. Then again, denying access to an unproven
intervention during an outbreak with high mortality and lack of effective treatment may
conflict with physicians’ duty of care to meet their patients’ best interests. This presentation
examines the application of WHO’s MEURI framework to the ethical provision of unproven
interventions to treat COVID-19 patients in Singapore.